financetom
Business
financetom
/
Business
/
KKR to Invest $326.5 Million to Support CleanPeak Energy
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
KKR to Invest $326.5 Million to Support CleanPeak Energy
Jul 28, 2025 1:07 AM

03:57 AM EDT, 07/28/2025 (MT Newswires) -- KKR (KKR) said Sunday it has agreed to invest 500 million Australian dollars ($326.5 million) to support CleanPeak Energy in expanding its solar power, battery storage and microgrid projects for businesses across Australia.

The company said the deal is set to close in the second half of 2025.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Drug-Trial Software Maker Clario Files Confidentially For IPO; Targets Valuation Of More Than $10 Billion- Bloomberg News
BRIEF-Drug-Trial Software Maker Clario Files Confidentially For IPO; Targets Valuation Of More Than $10 Billion- Bloomberg News
Jun 25, 2024
June 25 (Reuters) - * DRUG-TRIAL SOFTWARE MAKER CLARIO FILES CONFIDENTIALLY FOR IPO; TARGETS VALUATION OF MORE THAN $10 BILLION- BLOOMBERG NEWS Source text: https://bit.ly/4ceCjgt ...
Market Chatter: Google Developing Customizable Chatbots to Rival Meta, Character.AI
Market Chatter: Google Developing Customizable Chatbots to Rival Meta, Character.AI
Jun 25, 2024
03:16 PM EDT, 06/25/2024 (MT Newswires) -- Alphabet's (GOOG, GOOGL) Google ( GOOG ) is developing a product to create and converse with customizable chatbots to rival similar offerings from Meta Platforms ( META ) and Character.AI, The Information reported late Monday, citing two people with direct knowledge of the project. The chatbots, which could be modeled on celebrities or...
Arrowhead Pharmaceuticals to Advance Investigational Medicine Plozasiran Into Late-stage Cardiovascular Study
Arrowhead Pharmaceuticals to Advance Investigational Medicine Plozasiran Into Late-stage Cardiovascular Study
Jun 25, 2024
03:08 PM EDT, 06/25/2024 (MT Newswires) -- Arrowhead Pharmaceuticals ( ARWR ) said Tuesday it plans to advance its investigational medicine plozasiran into a late-stage cardiovascular study. The phase 3 Capitan trial will enroll patients with residual risk of atherosclerotic cardiovascular disease and mixed hyperlipidemia, a condition characterized by high levels of fats in the blood, the drugmaker said. Arrowhead...
National Bank Forecasts
National Bank Forecasts "Resilient" EPS Performance in Loblaw Q2 Preview
Jun 25, 2024
03:13 PM EDT, 06/25/2024 (MT Newswires) -- Loblaw ( LBLCF ) reports second quarter results on July 25. National Bank is forecasting second quarter earnings per share of $2.14, versus consensus at $2.15; last year was $1.94. Our projection of 10.1% y/y EPS growth reflects positive Food Retail same store sales growth, continued momentum in Shoppers Drug Mart, benefits from...
Copyright 2023-2026 - www.financetom.com All Rights Reserved